HER2-low unresectable and/or metastatic breast cancer in Russia

Trial Identifier: D133HR00029
Sponsor: AstraZeneca
NCTID:: NCT05913440
Start Date: May 2023
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Balashikha, Russia
Russia Barnaul, Russia
Russia Belgorod, Russia
Russia Chelyabinsk, Russia
Russia Chita, Russia
Russia Grozny, Russia
Russia Irkutsk, Russia
Russia Istra, Russia
Russia Izhevsk, Russia
Russia Kaluga, Russia
Russia Kazan, Russia
Russia Kemerovo, Russia
Russia Khanty-Mansiysk, Russia
Russia Khimki, Russia
Russia Kirov, Russia
Russia Klin, Russia
Russia Kolomna, Russia
Russia Korolev, Russia
Russia Kostroma, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Makhachkala, Russia
Russia Maykop, Russia
Russia Moscow, Russia
Russia Nalchik, Russia
Russia Nizhny Novgorod, Russia
Russia Novokuznetsk, Russia
Russia Novosibirsk, Russia
Russia Noyabrsk, Russia
Russia Omsk, Russia
Russia Orenburg, Russia
Russia Perm, Russia
Russia Plievo, Russia
Russia Podolsk, Russia
Russia Pyatigorsk, Russia
Russia Rostov-on-Don, Russia
Russia Ryazan, Russia
Russia Saint Petersburg, Russia
Russia Samara, Russia
Russia Saransk, Russia
Russia Saratov, Russia
Russia Sevedorvinsk, Russia
Russia Sochi, Russia
Russia Surgut, Russia
Russia Syktyvkar, Russia
Russia Tomsk, Russia
Russia Tver, Russia
Russia Ufa, Russia
Russia Ulan-Ude, Russia
Russia Ulyanovsk, Russia
Russia Vladivostok, Russia
Russia Volgograd, Russia
Russia Voronezh, Russia
Russia Yaroslavl, Russia
Russia Yekaterinburg, Russia
Russia Yuzhno-Sakhalinsk, Russia